Abstract 1877P
Background
After completion of curative cancer treatment patients enter the re-entry phase, which is characterized by the difficult task to pick up life again. In the re-entry patients face existential concerns, besides physical and psychosocial concerns. Finding meaning and purpose in this new situation may help in dealing with existential concerns. More insight is needed in the existential concerns and the meaning-making process in order to support patients in the re-entry phase.
Methods
We conducted 6 focus groups with 16 patients (5 patients with melanoma and 11 with breast cancer) during the re-entry phase, defined as the point from completion of treatment (after surgical treatment and adjuvant systemic treatment, except for hormonal therapy) up to 18 months in remission. A thematic content analysis was performed by two researchers.
Results
In general, patients experienced existential concerns regarding their worldview, inner posture, values and the future. In addition, patients with melanoma struggled with trust and responsibility for their health; patients with breast cancer struggled with relationships and identity. Outcomes of the meaning-making process identified were: meaning is affected and gives distress, existing sources of meaning are helpful, search for meaning or new meaning has been found. These outcomes were found at the beginning as well as further into the re-entry, however during the re-entry the focus of the meaning-making process shifted from the disease to (picking up) life.
Conclusions
The transition from being a patient to picking up daily life in the re-entry phase involves dealing with existential concerns causing distress. Patients use existing sources of meaning, search for new meaning or have found new meaning in order to deal with these existential concerns and distress. A meaning-centered intervention increasing patients awareness of their personal sources of meaning might strengthen their meaning-making process and can help in dealing with existential concerns.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
A. Visser and L. Post.
Funding
Novartis b.v.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2018P - Novel nomogram based on the expression of DLL3 and PD-L1 for predicting the prognosis of small cell lung cancer patients
Presenter: Jun Zhao
Session: Poster session 05
2019P - Analysis of lung immune prognostic index (LIPI) score in a small cell lung cancer carcinoma (SCLC) cohort, supporting its prognostic use and investigating its predictive potential
Presenter: Mónica Esteban García
Session: Poster session 05
2020P - Circulating micro RNAs (cmiRNAs) as treatment outcome predictors in extensive small cell lung cancer (eSCLC) patients (pts) receiving atezolizumab plus carboplatin and etoposide (ACE): CATS/ML43257 study
Presenter: Giulia Pasello
Session: Poster session 05
2021P - Cell-free (cf) DNA as predictive biomarker (B) of treatment outcome in extensive small cell lung cancer (eSCLC) patients (pts) receiving atezolizumab, carboplatin and etoposide (ACE): CATS/ML43257 study
Presenter: Giulia Pasello
Session: Poster session 05
2022P - ALBA project: Prognostic impact of laterality in small cell lung cancer
Presenter: Lorenza Landi
Session: Poster session 05
2024P - Supportive measures to control myelosuppression and costs for patients with SCLC with lurbinectedin, CAV or topotecan with or without trilaciclib: A review on the basis of clinical trials
Presenter: Manuel Dómine
Session: Poster session 05
2025P - Stratified control study of neuroendocrine differentiation and potential clinicopathologic markers
Presenter: Li Liu
Session: Poster session 05
2026P - Small cell lung cancer (SCLC) in the KBP-2020-CPHG cohort and comparison with 2000 and 2010
Presenter: Lionel Falchero
Session: Poster session 05
2027P - Immune checkpoint inhibitors in the treatment of small cell lung cancer: A systematic review and meta-analysis
Presenter: Patsy Lee
Session: Poster session 05